TGFB1 and cervical carcinoma: PD-1/CTLA-4 and PD-L1/TGF-β BSABs demonstrate comparable efficacy (ORR, 33% and 28.2%, respectively) in patients with advanced cervical cancer who have not received immunosuppressive therapy [181, 193].